PORTFOLIO

WE TARGET HEALTHCARE ASSETS WITH SIGNIFICANT CLINICAL VALUE AND STRONG BARRIERS TO ENTRY

that are marketed by some of the world’s largest pharmaceutical companies. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology and specialty pharmaceutical sectors.

Interview with Dr. Greg Went, Former Chairman & CEO, Adamas Pharmaceuticals (December 2017)

Interview with Julie Anne Smith, Former President and CEO, Raptor Pharmaceuticals

Spotlight

Royalty Monetization

Bayer AG

Royalty Monetization $300 Million

JUN 2025

IPSEN

Royalty Monetization Up to €185 million

JAN 2025

TLX250-CDx

Royalty Monetization Up to $115 MILLION

MAR 2024

CSL Vifor/Maruishi Pharma

ROYALTY MONETIZATION Up to $40 Million

Nov 2023

ELANCO

Royalty Monetization

AUG 2023

BAUSCH HEALTH COMPANIES

ROYALTY MONETIZATION UP TO $110 MILLION*

AUG 2023

SANOFI

ROYALTY MONETIZATION

JUL 2023

CSL Limited

Royalty Monetization Up to $400 Million

May 2023

EBVALLO

Pierre Fabre

ROYALTY MONETIZATION $31 Million

Dec 2022

Bausch + Lomb, RegenexBio, etc.

ROYALTY MONETIZATION Up to $65 Million

Aug 2022

Bausch + Lomb

ROYALTY MONETIZATION Up to $113 Million

Jan 2023/Mar 2022

TENAPANOR

Kyowa Kirin Co., Ltd.

ROYALTY MONETIZATION Up to $20 Million

Jun 2022

Pfizer

ROYALTY MONETIZATION Up to $67.5 Million

Mar 2021

VAFSEO

Mitsubishi Tanabe Pharma Corporation

ROYALTY MONETIZATION UP TO $60 MILLION

Feb 2021

Novartis AG

ROYALTY MONETIZATION $200 Million

Dec 2020

RedHill Biopharma

ROYALTY MONETIZATION

Dec 2020

Takeda Pharmaceutical Co. Ltd.

ROYALTY MONETIZATION

DEC 2020

UCB SA

ROYALTY MONETIZATION

Aug 2020

GLAXOSMITHKLINE PLC

Royalty Notes $200 Million

Mar 2020

Almirall

Royalty Note $32.5 Million

Feb 2019

Verastem Oncology

Royalty Monetization $50 million

MAR 2019

GlaxoSmithKline plc

Royalty Monetization $230 Million

Jan 2018

EA Pharma Co., Ltd

ROYALTY MONETIZATION $60 Million

Jun 2020 / Dec 2017

Biogen, Inc.

ROYALTY MONETIZATION $40 Million

Nov 2017

Roche/Genentech

Royalty Note $45 Million

Mar 2017

Pfizer

Royalty Monetization Up to $11 Million

Dec 2016

Salix

Royalty Note $50 Million

Nov 2016

Inavir^®

Daiichi Sankyo

Royalty Monetization $20 Million

Apr 2016

United Therapeutics

Royalty Monetization $30 Million

Jul 2014

Pfizer

Royalty Monetization $290 Million

Aug 2013

Astellas Europe

Royalty Monetization $18 Million

Jun 2012

Merck Serono

Royalty Monetization $55 Million

Nov 2008

Galderma/Allergan

Royalty Monetization $23 Million

Oct 2008

ViiV/GSK

Royalty Monetization $61 Million

May 2008

Corporate Financing

BEYONTTRA

Royalty Monetization $300 Million

JUN 2025

Various

Royalty Bond Up to $250 Million

May 2025

YUTREPIA™, Treprostinil

Non-Dilutive Financing Up to $200 Million

MAR 2025 / SEP 2024 / JAN 2024 / JUL 2023 / JAN 2023

IQIRVO®

Royalty Monetization Up to €185 million

JAN 2025

NEXLETOL®, NEXLIZET®

Senior Debt $150 million

Dec 2024

BRIUMVI®

Debt Financing $250 Million

AUG 2024

Genotropin / Ngenla

Limited Recourse Loan $250 Million

JUL 2024

XPOVIO^TM

Senior Secured Notes / Convertible Notes $20 Million

May 2024

Rare Disease Assets

Senior Debt Up to $100 million

APR 2024

TLX250-CDx

Royalty Monetization Up to $115 Million

MAR 2024

Korsuva/Kapruvia

ROYALTY MONETIZATION Up to $40 Million

Nov 2023

Bexacat

ROYALTY MONETIZATION

AUG 2023

RELISTOR®

ROYALTY MONETIZATION UP TO $110 MILLION*

AUG 2023

Hemgenix^®

ROYALTY MONETIZATION Up to $400 Million

May 2023

EBVALLO

ROYALTY MONETIZATION $31 Million

Dec 2022

XIPERE, ARVN001, RGX-314, AU-011

ROYALTY MONETIZATION Up to $65 Million

Aug 2022

TENAPANOR

ROYALTY MONETIZATION Up to $20 Million

JUN 2022

IMCIVREE

Synthetic Royalty^TM Financing Up to $100 Million

Jun 2022

Tebipenem HBr

Synthetic Royalty^TM Financing Up to $125 Million

Sep 2021

ZYNLONTA^TM

Synthetic Royalty^TM Financing Up to $325 Million

Aug 2021

Ruxience

ROYALTY MONETIZATION Up to $67.5 Million

Mar 2021

VAFSEO

ROYALTY MONETIZATION UP TO $60 MILLION

Feb 2021

ZOLGENSMA^®

ROYALTY MONETIZATION $200 Million

DEC 2020

ADYNOVATE^®, MOVANTIK^®

ROYALTY MONETIZATION $150 million

DEC 2020

MYCAPSSA^®

SYNTHETIC ROYALTY^TM / DEBT FINANCING Up to $75 Million

APR 2020

Movantik®, Talicia®, Aemcolo®

Senior Secured Debt with fixed and contingent interest Up to $115 Million

Feb 2020

Trelegy Ellipta

Royalty Notes $200 Million

Mar 2020

XPOVIO^TM

Synthetic Royalty^TM Up to $175 Million

JUN 2021/SEP 2019

ANDEXXA^®

Senior Secured Debt $125 million

MAR 2019

UDENYCA^®

Structured Credit $75 Million

Jan 2019

GIAPREZA^TM (angiotensin II)

Synthetic Royalty^TM Financing $125 million

May 2018

QS-21 containing vaccines

ROYALTY MONETIZATION $230 MILLION

JAN 2018

GOOFICE^®

ROYALTY MONETIZATION $60 MILLION

JUN 2020 / DEC 2017

FAMPYRA^®

ROYALTY MONETIZATION $40 Million

Nov 2017

RELISTOR^®

Royalty Note $50 Million

Nov 2016

TRUMENBA^®

ROYALTY MONETIZATION Up to $11 Million

Dec 2016

Erivedge^®

Royalty Note $45 Million

Mar 2017

CNS Assets

Royalty Note $100 Million

May 2017

ANDEXXA^®

Synthetic Royalty^TM Financing $150 Million

Feb 2017

VELTASSA^®

Structured Credit $150 Million

May 2016

Biosimilars Platform

Convertible Notes $100 Million

Feb 2016

PROCYSBI^®

Convertible Notes / Senior Debt $120 Million

Jul 2014

Phage Display Platform

Structured Credit $80 million

Dec 2011

PORTFOLIO

WE TARGET HEALTHCARE ASSETS WITH SIGNIFICANT CLINICAL VALUE AND STRONG BARRIERS TO ENTRY

Royalty Monetization

TLX250-CDx

EBVALLO

TENAPANOR

VAFSEO

Inavir®

Corporate Financing

VIEW THE COMPLETE LIST OF HCRx INVESTMENTS

Inavir^®